The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments.
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S...
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a...
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and...
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The...
Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -1.46596858639 | 9.55 | 9.55 | 9.2619 | 2759 | 9.37749565 | CS |
4 | -0.04 | -0.42328042328 | 9.45 | 9.55 | 9.16 | 2128 | 9.35669594 | CS |
12 | 0.14 | 1.51024811219 | 9.27 | 9.93 | 8.9 | 1851 | 9.33880225 | CS |
26 | 0.28 | 3.06681270537 | 9.13 | 9.93 | 8.72 | 2682 | 9.28180154 | CS |
52 | 0.61 | 6.93181818182 | 8.8 | 10.19 | 7.93 | 3063 | 9.02011817 | CS |
156 | 0.21 | 2.28260869565 | 9.2 | 11.25 | 7.8 | 4660 | 9.07988666 | CS |
260 | 1.35 | 16.7493796526 | 8.06 | 11.25 | 5.2 | 4880 | 8.36286227 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.